S 355: FDA Modernization Act 3.0

S 355 in plain English: This bill directs the FDA to publish a new rule within one year that replaces requirements for animal testing with broader 'nonclinical' testing options when companies apply to investigate new drugs. It implements a provision already passed in the Consolidated Appropriations Act of 2023 that allowed alternatives to animal testing.

Stated purpose

This bill requires the FDA to update its official regulations within one year to recognize alternatives to animal testing — called 'nonclinical tests' — as valid methods for supporting applications to study new drugs in humans, implementing a change that Congress already authorized in 2023.

Key points

• Requires the FDA to publish an interim final rule within one year of enactment
• Replaces animal testing language with 'nonclinical' testing language across FDA drug application regulations
• Implements an animal testing alternative provision from the Consolidated Appropriations Act of 2023
• The rule takes immediate effect upon publication as an interim final rule

Arguments supporters make

• Modern testing tools like organ-on-a-chip models and computer simulations can be more accurate predictors of human response than animal tests, potentially making drug development faster and safer.
• Congress already approved allowing these alternatives in 2023, so this bill simply forces the FDA to update its paperwork to match the law — removing an unnecessary barrier that has slowed implementation.
• Reducing reliance on animal testing addresses serious ethical concerns about animal suffering without sacrificing the scientific rigor needed to protect patients.

Arguments opponents make

• Bypassing the normal public comment process to make the rule immediately effective removes an important safeguard that allows scientists, doctors, and the public to flag problems before regulations take hold.
• Animal testing has decades of established safety data behind it, and switching to less-proven alternatives could introduce unforeseen risks for patients in clinical trials if the new methods miss dangerous side effects.
• The one-year deadline may pressure the FDA to rush complex regulatory rewrites across many sections of its rules, potentially creating inconsistencies or gaps that could complicate drug review processes.

Tradeoffs

Moving quickly to recognize alternative testing methods may speed up drug development and reduce animal use, but doing so through an immediately effective rule — without the usual period for public feedback — trades procedural caution for speed, which may reduce opportunities to catch errors before the rules are in force.

Current status in Congress: Passed Senate.

NewsClear — neutral news & congressional tracking · Bill of the Week